Status:

COMPLETED

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

Bristol-Myers Squibb

Beth Israel Deaconess Medical Center

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such ...

Detailed Description

Patients will receive both carboplatin and docetaxel. This treatment is given in the outpatient department once every 3 weeks (called one cycle). One day prior to the day of chemotherapy, patients ar...

Eligibility Criteria

Inclusion

  • Histologically confirmed adenocarcinoma of the prostate
  • Evidence of metastatic disease
  • Disease progression following androgen deprivation therapy
  • Disease progression despite docetaxel-based chemotherapy
  • Serum testosterone levels less than 50ng/ml (unless surgically castrated). Patients must continue androgen deprivation with a luteinizing hormone-releasing hormone (LHRH) analogue if they have not undergone orchiectomy.
  • No use of antiandrogens for at least 4 weeks
  • Cancer and Leukemia Group B (CALGB) performance status less than or equal to 2
  • Acceptable white blood cell (WBC), platelets, creatinine and AST counts

Exclusion

  • Significant peripheral neuropathy defined as grade 2 or higher
  • Within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium)
  • Prior platinum-based chemotherapy (cisplatin or carboplatin) for hormone- refractory prostate cancer
  • Concomitant chemotherapy, investigational agents or systemic steroids

Key Trial Info

Start Date :

January 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2009

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00134706

Start Date

January 1 2004

End Date

September 1 2009

Last Update

December 9 2009

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

3

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

4

Lowell General Hospital

Lowell, Massachusetts, United States, 01854